LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

Home・Lista de Ações・Ovid therapeutics Inc

Ovid therapeutics Inc

Fechado

SetorSaúde

2.35 -1.26

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

2.32

Máximo

2.42

Indicadores-chave
By Trading Economics
Rendimento	-27M -17M
EPS	-0.125
Margem de lucro	-2,366.017
Funcionários	23
EBITDA	-5.5M -18M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+122.08% upside

Dividendos
By Dow Jones
Próximos Ganhos	12 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-5M 478M
Abertura anterior	3.61
Fecho anterior	2.35

Sentimento de Notícias

By Acuity

50%

161 / 344 Ranking em Healthcare

Ovid therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

8 de jun. de 2026, 22:20 UTC

Aquisições, Fusões, Aquisições de Empresas

Salesforce to Buy m3ter in Nod Toward AI-Native Business Models

8 de jun. de 2026, 15:41 UTC

Grandes Movimentos do Mercado

American Battery Shares Jump on Energy Department Victory

8 de jun. de 2026, 23:46 UTC

Conversa de Mercado

Nikkei May Rebound After Monday's Selloff -- Market Talk

8 de jun. de 2026, 23:37 UTC

Conversa de Mercado

Oil Edges Higher Amid Ongoing Supply Disruption Concerns -- Market Talk

8 de jun. de 2026, 23:25 UTC

Conversa de Mercado

Should Australia Consider State-Linked Commodities Export Desk? -- Market Talk

8 de jun. de 2026, 23:25 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

8 de jun. de 2026, 21:57 UTC

Aquisições, Fusões, Aquisições de Empresas

Salesforce Expects to Close Deal in 2Q of Fiscal 2027

8 de jun. de 2026, 21:56 UTC

Aquisições, Fusões, Aquisições de Empresas

Salesforce Agrees to Buy m3ter

8 de jun. de 2026, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

8 de jun. de 2026, 19:22 UTC

Conversa de Mercado

Oil Settles Higher as Israel-Iran Exchanges Raise Tension -- Market Talk

8 de jun. de 2026, 19:01 UTC

Conversa de Mercado

U.S. Natural Gas Futures Pull Back on Weather Outlook -- Market Talk

8 de jun. de 2026, 18:52 UTC

Conversa de Mercado

Global Energy Roundup: Market Talk

8 de jun. de 2026, 18:52 UTC

Conversa de Mercado

CAD Needs Trade Deal to Trigger Sustained Rally -- Market Talk

8 de jun. de 2026, 18:17 UTC

Conversa de Mercado

Oil Pulls Back Further As Iran, Israel Put Strikes on Hold -- Market Talk

8 de jun. de 2026, 17:32 UTC

Conversa de Mercado

Bank of Canada Should Incorporate Unemployment Rate Into Its Forecast -- Market Talk

8 de jun. de 2026, 17:29 UTC

Conversa de Mercado

Crypto Market Still Stays in 'Extreme Fear' Amid Rebound -- Market Talk

8 de jun. de 2026, 17:29 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

8 de jun. de 2026, 16:55 UTC

Aquisições, Fusões, Aquisições de Empresas

Monte dei Paschi: Mediobanca Integration Proceeding According to Plan

8 de jun. de 2026, 16:54 UTC

Aquisições, Fusões, Aquisições de Empresas

Monte dei Paschi to Review Proposals From Banco BPM, Intesa Sanpaolo

8 de jun. de 2026, 16:40 UTC

Conversa de Mercado

Cryptocurrencies Rise After Iran and Israel Halt Exchanges of Fire -- Market Talk

8 de jun. de 2026, 16:31 UTC

Conversa de Mercado

No Recession in Canada, Scotiabank's CEO Says -- Market Talk

8 de jun. de 2026, 16:27 UTC

Conversa de Mercado

Mexican Inflation Seen Easing in May -- Market Talk

8 de jun. de 2026, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

8 de jun. de 2026, 16:03 UTC

Aquisições, Fusões, Aquisições de Empresas

Orange Bought Stake From Lorca

8 de jun. de 2026, 16:01 UTC

Aquisições, Fusões, Aquisições de Empresas

Orange Completes Acquisition of Remaining 50% Stake in MasOrange

8 de jun. de 2026, 16:01 UTC

Aquisições, Fusões, Aquisições de Empresas

Orange Acquires 100% Ownership of MasOrange

8 de jun. de 2026, 15:58 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

8 de jun. de 2026, 15:58 UTC

Conversa de Mercado

Gold Trims Losses After Israel, Iran Halt Exchanges of Fire -- Market Talk

8 de jun. de 2026, 15:55 UTC

Conversa de Mercado

Markets Price Small Chance USMCA Will Be Dismantled -- Market Talk

8 de jun. de 2026, 15:41 UTC

Conversa de Mercado

Gold Falls Below 200-Day Moving Average -- Market Talk

Comparação entre Pares

Variação de preço

Ovid therapeutics Inc Previsão

Preço-alvo

By TipRanks

122.08% parte superior

Previsão para 12 meses

Média 5.33 USD 122.08%

Máximo 7 USD

Mínimo 4 USD

Com base em 8 analistas de Wall Street que oferecem metas de preço de 12 meses para Ovid therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

8 ratings

Comprar

Manter

Vender

Com base em 8 analistas que deram avaliações de ações para Ovid therapeutics Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

161 / 344 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Ovid therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.